phase iii ahead 3-45 trial of lecanemab for preclinical alzheimer’s disease
Published 3 years ago • 549 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
2:02
lecanemab for the treatment of early alzheimer’s disease: the story so far
-
0:49
time saved in alzheimer’s disease in phase iii trial of donanemab
-
1:32
major ongoing clinical trials in ad: aducanumab, donanemab & lecanemab
-
1:38
the potential of lecanemab for the treatment of early alzheimer’s disease
-
1:31
phase ii study of lecanemab in early ad
-
1:23
updates in pharmacological treatment of alzheimer’s disease: lecanemab, donanemab and gantenerumab
-
2:32
lecanemab phase 3 drug study shows better results in treatment of alzheimer's disease
-
0:39
alzheimer's and amyloid #alzheimer
-
6:01
the development of lecanemab & rationale behind its unique binding profile
-
3:02
lecanemab: drawbacks to consider
-
4:01
comparing binding characteristics to aβ of lecanemab, aducanumab & gantenerumab
-
36:22
a closer look at the lecanemab clinical trials | special video episode of dementia matters
-
17:28
lecanemab: a potential new drug for alzheimer's disease
-
4:57
open-label extension study of lecanemab in early alzheimer’s disease
-
4:59
lecanemab: phase ii open-label extension results
-
1:25:31
lecanemab for treatment of early alzheimer’s disease: overview & clinician perspectives
-
0:41
eisai co (4523 jp): positive trial result for alzheimer’s disease drug- a step closer to approval
-
0:09
fda grants approval for alzheimer’s drug lecanemab | #mcashorts
-
2:20
the ability of plasma p-tau231 to detect preclinical alzheimer’s disease